ID

23562

Description

Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1); ODM derived from: https://clinicaltrials.gov/show/NCT00308139

Lien

https://clinicaltrials.gov/show/NCT00308139

Mots-clés

Versions (1)
  1. 09/07/2017 09/07/2017 -
Détendeur de droits

Study Director: Lisa Porter, MD Amylin Pharmaceuticals, LLC.

Téléchargé le

9 juillet 2017

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY-NC 3.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Type 2 Diabetes Mellitus NCT00308139

Anglais

Eligibility Type 2 Diabetes Mellitus NCT00308139

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
has type 2 diabetes mellitus treated with diet modification and exercise alone or in combination with a stable regimen of a combination of metformin, sulphonylureas, and thiazolidinediones for a minimum of 2 months at screening.
Description

diabetes mellitus type 2 with diet modification, exercise, metformin, sulfonylureas, thiazolidinediones

Type de données

boolean

Alias
UMLS CUI [1,1]
C0011860
UMLS CUI [1,2]
C0086153
UMLS CUI [1,3]
C0015259
UMLS CUI [1,4]
C0025598
UMLS CUI [1,5]
C3653359
UMLS CUI [1,6]
C1257987
hemoglobin a1c (hba1c) of 7.1% to 11.0%, inclusive, at screening.
Description

hba1c

Type de données

boolean

Alias
UMLS CUI [1]
C0019018
body mass index (bmi) of 25 kg/m2 to 45 kg/m2, inclusive, at screening.
Description

bmi

Type de données

boolean

Alias
UMLS CUI [1]
C1305855
(for sub-study) currently participating in open ended assessment period of main study 2993 lar105
Description

study participation

Type de données

boolean

Alias
UMLS CUI [1]
C2348568
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
has been previously exposed to exenatide (byetta®), exenatide lar, or any glucagon-like peptide-1 (glp-1) analog.
Description

exenatide, glucagon-like peptide 1

Type de données

boolean

Alias
UMLS CUI [1]
C0167117
UMLS CUI [2]
C0061355
received any investigational drug or has participated in any type of clinical trial within 30 days prior to screening.
Description

investigational drug, study participation

Type de données

boolean

Alias
UMLS CUI [1]
C0013230
UMLS CUI [2]
C2348568
has been treated, is currently treated, or is expected to require or undergo treatment with any of the following excluded medications:
Description

excluded medications

Type de données

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C2828389
alpha glucosidase inhibitor or meglitinide within 30 days of screening;
Description

alpha glucosidase inhibitor, meglitinide

Type de données

boolean

Alias
UMLS CUI [1]
C3539108
UMLS CUI [2]
C0065880
insulin within 2 weeks prior to screening or insulin for longer than 1 week within 3 months of screening;
Description

insulin

Type de données

boolean

Alias
UMLS CUI [1]
C0021641
regular use (> 14 days) of drugs that directly affect gastrointestinal motility;
Description

gastrointestinal motility affecting drugs

Type de données

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C0017184
regular use (> 14 days) of systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary steroids known to have a high rate of systemic absorption;
Description

systemic corticosteroids

Type de données

boolean

Alias
UMLS CUI [1]
C2825233
regular use (> 14 days) of medications with addictive potential such as opiates and opioids;
Description

addictive drugs

Type de données

boolean

Alias
UMLS CUI [1]
C0813966
prescription or over-the-counter weight loss medications within 6 months of screening.
Description

over-the-counter weight loss medication

Type de données

boolean

Alias
UMLS CUI [1,1]
C0013231
UMLS CUI [1,2]
C0376606
(for sub-study) subjects will be terminated from study who do not participate in the dual chamber pen substudy
Description

study participation

Type de données

boolean

Alias
UMLS CUI [1]
C2348568
Retour au début de la page

Similar models

Eligibility Type 2 Diabetes Mellitus NCT00308139

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
diabetes mellitus type 2 with diet modification, exercise, metformin, sulfonylureas, thiazolidinediones
Item
has type 2 diabetes mellitus treated with diet modification and exercise alone or in combination with a stable regimen of a combination of metformin, sulphonylureas, and thiazolidinediones for a minimum of 2 months at screening.
boolean
C0011860 (UMLS CUI [1,1])
C0086153 (UMLS CUI [1,2])
C0015259 (UMLS CUI [1,3])
C0025598 (UMLS CUI [1,4])
C3653359 (UMLS CUI [1,5])
C1257987 (UMLS CUI [1,6])
hba1c
Item
hemoglobin a1c (hba1c) of 7.1% to 11.0%, inclusive, at screening.
boolean
C0019018 (UMLS CUI [1])
bmi
Item
body mass index (bmi) of 25 kg/m2 to 45 kg/m2, inclusive, at screening.
boolean
C1305855 (UMLS CUI [1])
study participation
Item
(for sub-study) currently participating in open ended assessment period of main study 2993 lar105
boolean
C2348568 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
exenatide, glucagon-like peptide 1
Item
has been previously exposed to exenatide (byetta®), exenatide lar, or any glucagon-like peptide-1 (glp-1) analog.
boolean
C0167117 (UMLS CUI [1])
C0061355 (UMLS CUI [2])
investigational drug, study participation
Item
received any investigational drug or has participated in any type of clinical trial within 30 days prior to screening.
boolean
C0013230 (UMLS CUI [1])
C2348568 (UMLS CUI [2])
excluded medications
Item
has been treated, is currently treated, or is expected to require or undergo treatment with any of the following excluded medications:
boolean
C0013227 (UMLS CUI [1,1])
C2828389 (UMLS CUI [1,2])
alpha glucosidase inhibitor, meglitinide
Item
alpha glucosidase inhibitor or meglitinide within 30 days of screening;
boolean
C3539108 (UMLS CUI [1])
C0065880 (UMLS CUI [2])
insulin
Item
insulin within 2 weeks prior to screening or insulin for longer than 1 week within 3 months of screening;
boolean
C0021641 (UMLS CUI [1])
gastrointestinal motility affecting drugs
Item
regular use (> 14 days) of drugs that directly affect gastrointestinal motility;
boolean
C0013227 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0017184 (UMLS CUI [1,3])
systemic corticosteroids
Item
regular use (> 14 days) of systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary steroids known to have a high rate of systemic absorption;
boolean
C2825233 (UMLS CUI [1])
addictive drugs
Item
regular use (> 14 days) of medications with addictive potential such as opiates and opioids;
boolean
C0813966 (UMLS CUI [1])
over-the-counter weight loss medication
Item
prescription or over-the-counter weight loss medications within 6 months of screening.
boolean
C0013231 (UMLS CUI [1,1])
C0376606 (UMLS CUI [1,2])
study participation
Item
(for sub-study) subjects will be terminated from study who do not participate in the dual chamber pen substudy
boolean
C2348568 (UMLS CUI [1])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial